1. Home
  2. CTMX vs TSSI Comparison

CTMX vs TSSI Comparison

Compare CTMX & TSSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • TSSI
  • Stock Information
  • Founded
  • CTMX 2008
  • TSSI 2004
  • Country
  • CTMX United States
  • TSSI United States
  • Employees
  • CTMX N/A
  • TSSI N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • TSSI Professional Services
  • Sector
  • CTMX Health Care
  • TSSI Consumer Discretionary
  • Exchange
  • CTMX Nasdaq
  • TSSI Nasdaq
  • Market Cap
  • CTMX 596.2M
  • TSSI 572.8M
  • IPO Year
  • CTMX 2015
  • TSSI N/A
  • Fundamental
  • Price
  • CTMX $3.39
  • TSSI $17.89
  • Analyst Decision
  • CTMX Strong Buy
  • TSSI
  • Analyst Count
  • CTMX 5
  • TSSI 0
  • Target Price
  • CTMX $5.80
  • TSSI N/A
  • AVG Volume (30 Days)
  • CTMX 3.0M
  • TSSI 2.2M
  • Earning Date
  • CTMX 11-07-2025
  • TSSI 11-21-2025
  • Dividend Yield
  • CTMX N/A
  • TSSI N/A
  • EPS Growth
  • CTMX 263.20
  • TSSI 311.74
  • EPS
  • CTMX 0.49
  • TSSI 0.34
  • Revenue
  • CTMX $141,100,000.00
  • TSSI $263,021,000.00
  • Revenue This Year
  • CTMX N/A
  • TSSI N/A
  • Revenue Next Year
  • CTMX N/A
  • TSSI N/A
  • P/E Ratio
  • CTMX $6.79
  • TSSI $51.88
  • Revenue Growth
  • CTMX 18.01
  • TSSI 328.79
  • 52 Week Low
  • CTMX $0.40
  • TSSI $5.63
  • 52 Week High
  • CTMX $3.91
  • TSSI $31.94
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 57.06
  • TSSI 50.52
  • Support Level
  • CTMX $3.21
  • TSSI $17.55
  • Resistance Level
  • CTMX $3.50
  • TSSI $19.00
  • Average True Range (ATR)
  • CTMX 0.25
  • TSSI 1.34
  • MACD
  • CTMX -0.06
  • TSSI -0.03
  • Stochastic Oscillator
  • CTMX 35.42
  • TSSI 40.77

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About TSSI TSS Inc. Common Stock

TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.

Share on Social Networks: